ARTVHealthcare · BiotechnologyThe 6 Wall Street analysts covering Artiva Biotherapeutics, Inc. hold a median 12-month price target of $20 — +362.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 4 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Artiva Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (67): The shares have been drifting up relative to others.
Value (12): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ARTV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +362.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Oct 2026 | Jefferies | Downgrade | Hold | $4.00 |
| 27 Oct 2026 | Needham | Downgrade | Hold | — |
| 27 Oct 2026 | Wedbush | Downgrade | Neutral | $40 → $4.00 |
| 2 Oct 2026 | Cantor Fitzgerald | Reiterates | Overweight | $40 |
| 2 Oct 2026 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 8 June 2026 | Needham | Reiterates | Buy | — |
| 8 June 2026 | Needham | Reiterates | Buy | $41 |
| 12 May 2026 | Needham | Maintains | Buy | — |
| 11 May 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 11 May 2026 | Wedbush | Maintains | Outperform | — |
| 8 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 May 2026 | Needham | Reiterates | Buy | — |
| 11 Mar 2026 | Needham | Reiterates | Buy | — |
| 12 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 Oct 2025 | Needham | Reiterates | Buy | — |
| 17 Oct 2025 | Wedbush | Maintains | Outperform | — |
| 11 June 2025 | HC Wainwright & Co. | Assumes | Buy | $12 |
| 15 May 2025 | Needham | Maintains | Buy | — |
| 8 Apr 2025 | Needham | Reiterates | Buy | — |
| 26 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ARTV appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Artiva Biotherapeutics, Inc. returned +17.5% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 84% of US stocks
Cheaper than 81% of US stocks
Cheaper than 57% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 25% of US stocks
Higher than 18% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Artiva Biotherapeutics, Inc. has a market value of $205.3M and an enterprise value of −$134.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$90.8M.
Free cash flow in the twelve months to 30 June 2026: −$76.9M.
Trailing P/E: −1.2×; forward P/E: −2.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Artiva Biotherapeutics, Inc. employs 115 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Artiva Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Artiva Biotherapeutics said it will halt further clinical development of its lead cell therapy candidate, cut roughly 94% of its workforce, and evaluate strategic alternatives.
Why it matters — The halted development and major workforce reduction mark significant changes to Artiva’s operations and strategic direction.
Artiva will discontinue development of AlloNK (AB-101), including its planned Phase 3 trial, after longer-term data showed response durability did not meet the company’s threshold and it reviewed recent Grade 5 events. The company also plans to reduce its workforce by approximately 94%, evaluate strategic alternatives, and reported preliminary unaudited cash, cash equivalents and investments of about $319.1 million as of September 30, 2026.
Why it matters — The decision ends development of a key candidate and is accompanied by a major workforce reduction and a review of strategic alternatives.
Artiva Biotherapeutics announced one oral and two poster presentations at ACR Convergence 2026 featuring updated data from its AlloNK program combined with rituximab across refractory rheumatoid arthritis, Sjögren disease, and systemic sclerosis, along with a registry analysis of unmet need in refractory RA. The company will host a live webcast on November 9, 2026 to review the presentations and updated clinical data.
Why it matters — ARTV watchers would care because the updated AlloNK data presentations highlight deep, consistent B-cell depletion and a favorable tolerability profile, with a subset of patients reported to meet key eligibility criteria for the planned Phase 3 registrational trial.
Artiva Biotherapeutics presented updated data on its AlloNK® therapy for Sjögren disease at the 17th International Symposium on Sjögren's Disease (ISSjD 2026). The presentation highlights the company's ongoing research in this indication.
Why it matters — The updated AlloNK data presentation signals continued progress in Artiva's clinical development pipeline for Sjögren disease.
Artiva Biotherapeutics announced that updated clinical data on its AlloNK (AB-101) cell therapy will be presented in an oral presentation at the 17th International Symposium on Sjögren's Disease, taking place September 29 through October 2, 2026, in Paris. The abstract covers AB-101 combined with rituximab in 11 patients with Sjögren disease.
Why it matters — An ARTV watcher would care because this oral presentation showcases updated clinical data for the company's lead AlloNK therapy in Sjögren disease, a key step in advancing its autoimmune disease pipeline.
The 6 Wall Street analysts covering Artiva Biotherapeutics, Inc. have a median 12-month price target of $20, with estimates ranging from $4 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Artiva Biotherapeutics, Inc., 2 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Artiva Biotherapeutics, Inc. 29 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Artiva Biotherapeutics, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (67 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +362.1% from the last close, and Ticker Nerd's factor model ranks Artiva Biotherapeutics, Inc. 29 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Artiva Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARTV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $40 over the next 12 months.
Artiva Biotherapeutics, Inc. returned +17.5% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for autoimmune diseases and cancers.
The most recent item we track (Benzinga, 27 Oct 2026): "Artiva Biotherapeutics Plunges Into Crisis Over Patient Deaths and Possible Liquidation". Artiva Biotherapeutics said it will halt further clinical development of its lead cell therapy candidate, cut roughly 94% of its workforce, and evaluate strategic alternatives.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for autoimmune diseases and cancers. The company’s current portfolio centers on allogeneic, off-the-shelf cell therapies designed to be pre-manufactured, cryopreserved, and delivered ready for use. Its lead program, AlloNK, is being studied in combination with B-cell targeted monoclonal antibodies across multiple autoimmune indications, including lupus nephritis and rheumatoid arthritis, as well as in certain B-cell malignancies. Artiva Biotherapeutics also advances additional NK cell therapy candidates aimed at addressing B-cell driven diseases and hematologic cancers. Based in San Diego, California, Artiva Biotherapeutics plays a specialized role in the cell therapy market by focusing on scalable immunotherapy platforms intended for use in both autoimmune and oncology settings.
CEO Dr. Fred Aslan M.D. · 115 employees · United States · https://www.artivabio.com
